{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:33:39Z","timestamp":1767987219779,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["no. 81700321"],"award-info":[{"award-number":["no. 81700321"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-023-10330-5","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T19:01:16Z","timestamp":1687892476000},"page":"1427-1436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MRAs may have lost their cornerstone position for heart failure treatment in the age of SGLT-2 inhibitors: A meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"28","author":[{"given":"Xiangfeng","family":"Guan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanzhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zifan","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianlong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunhe","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"issue":"22","key":"10330_CR1","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128","journal-title":"N Engl J Med"},{"issue":"7","key":"10330_CR2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657","journal-title":"N Engl J Med"},{"issue":"4","key":"10330_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u2013357","journal-title":"N Engl J Med"},{"issue":"24","key":"10330_CR4","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295\u20132306","journal-title":"N Engl J Med"},{"key":"10330_CR5","doi-asserted-by":"crossref","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B\u00a0et al (2003)\u00a0Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published correction appears in N Engl J Med 348(22):2271]. N Engl J Med 348(14):1309\u20131321","DOI":"10.1056\/NEJMoa030207"},{"issue":"1","key":"10330_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11\u201321","journal-title":"N Engl J Med"},{"key":"10330_CR7","doi-asserted-by":"crossref","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al (1999)\u00a0The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709\u2013717","DOI":"10.1056\/NEJM199909023411001"},{"issue":"21","key":"10330_CR8","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008","journal-title":"N Engl J Med"},{"issue":"15","key":"10330_CR9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424","journal-title":"N Engl J Med"},{"issue":"10254","key":"10330_CR10","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G et al (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 396(10254):819\u2013829","journal-title":"Lancet"},{"key":"10330_CR11","doi-asserted-by":"crossref","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM\u00a0et al (2022)\u00a02022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2022 May 3;145(18):e1033] [published correction appears in Circulation. 2022 Sep 27;146(13):e185]. Circulation 145(18):e895\u2013e1032","DOI":"10.1161\/CIR.0000000000001073"},{"key":"10330_CR12","doi-asserted-by":"crossref","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM et al (2017) 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136(6):e137\u2013e161","DOI":"10.1161\/CIR.0000000000000509"},{"issue":"10244","key":"10330_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","volume":"396","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F et al (2020) Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet 396(10244):121\u2013128","journal-title":"Lancet"},{"key":"10330_CR14","doi-asserted-by":"crossref","unstructured":"Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF\u00a0et al (2022)\u00a0\u00a0SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials [published correction appears in Lancet. 2023 Jan 14;401(10371):104]. Lancet 400(10354):757\u2013767","DOI":"10.1016\/S0140-6736(22)01429-5"},{"issue":"11","key":"10330_CR15","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","volume":"77","author":"JP Ferreira","year":"2021","unstructured":"Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos G et al (2021) Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. J Am Coll Cardiol 77(11):1397\u20131407","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10330_CR16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jchf.2020.11.009","volume":"9","author":"L Shen","year":"2021","unstructured":"Shen L, Kristensen SL, Bengtsson O, B\u00f6hm M, de Boer RA, Docherty KF et al (2021) Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF. JACC Heart Fail 9(4):254\u2013264","journal-title":"JACC Heart Fail"},{"key":"10330_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700","journal-title":"BMJ"},{"issue":"31","key":"10330_CR18","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H et al (2013) Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 34(31):2453\u20132463","journal-title":"Eur Heart J"},{"key":"10330_CR19","doi-asserted-by":"crossref","unstructured":"Tromp J, Ouwerkerk W, van Veldhuisen DJ, Hillege HL, Richards AM, van der Meer P et al (2022) A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction [published correction appears in JACC Heart Fail. 2022 Apr;10(4):295\u2013296].\u00a0JACC Heart Fail 10(2):73\u201384","DOI":"10.1016\/j.jchf.2021.09.004"},{"issue":"2","key":"10330_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/joim.13487","volume":"292","author":"V De Marzo","year":"2022","unstructured":"De Marzo V, Savarese G, Tricarico L, Hassan S, Iacoviello M, Porto I et al (2022) Network meta-analysis of medical therapy efficacy in more than 90,000 patients with heart failure and reduced ejection fraction. J Intern Med 292(2):333\u2013349","journal-title":"J Intern Med"},{"issue":"4","key":"10330_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104","volume":"7","author":"O Vardeny","year":"2014","unstructured":"Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F et al (2014) Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 7(4):573\u2013579","journal-title":"Circ Heart Fail"},{"issue":"20","key":"10330_CR22","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","volume":"60","author":"O Vardeny","year":"2012","unstructured":"Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B et al (2012) Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 60(20):2082\u20132089","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10330_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","volume":"7","author":"P Rossignol","year":"2014","unstructured":"Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ et al (2014) Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 7(1):51\u201358","journal-title":"Circ Heart Fail"},{"issue":"9","key":"10330_CR24","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1097\/01.ASN.0000083982.74108.54","volume":"14","author":"S Arima","year":"2003","unstructured":"Arima S, Kohagura K, Xu HL, Sugawara A, Abe T, Satoh F et al (2003) Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 14(9):2255\u20132263","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10330_CR25","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S (2020) Mechanisms of cardiovascular benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: a state-of-the-art review. JACC Basic Transl Sci 5(6):632\u2013644","journal-title":"JACC Basic Transl Sci"},{"issue":"11","key":"10330_CR26","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","volume":"142","author":"M Griffin","year":"2020","unstructured":"Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C et al (2020) Empagliflozin in heart failure: diuretic and cardiorenal effects. Circulation 142(11):1028\u20131039","journal-title":"Circulation"},{"key":"10330_CR27","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M\u00a0et al (2021) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [published correction appears in Eur Heart J. 2021 Oct 14]. Eur Heart J 42(36):3599\u20133726"},{"issue":"12","key":"10330_CR28","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1111\/dom.13855","volume":"21","author":"CCJ Dekkers","year":"2019","unstructured":"Dekkers CCJ, Sj\u00f6str\u00f6m CD, Greasley PJ, Cain V, Boulton DW, Heerspink HJL (2019) Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diabetes Obes Metab 21(12):2667\u20132673","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10330_CR29","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A et al (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129(5):587\u2013597","journal-title":"Circulation"},{"issue":"6","key":"10330_CR30","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3390\/jcm8060779","volume":"8","author":"MK Eickhoff","year":"2019","unstructured":"Eickhoff MK, Dekkers CCJ, Kramers BJ, Laverman GD, Frimodt-M\u00f8ller M, J\u00f8rgensen NR et al (2019) Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors. J Clin Med 8(6):779","journal-title":"J Clin Med"},{"key":"10330_CR31","doi-asserted-by":"crossref","unstructured":"Zanchi A, Burnier M, Muller ME, Ghajarzadeh-Wurzner A, Maillard M, Loncle N et al (2020) Acute and chronic effects of SGLT2 inhibitor empagliflozin on renal oxygenation and blood pressure control in nondiabetic normotensive subjects: a randomized, placebo-controlled trial. J Am Heart Assoc 9(13):e016173","DOI":"10.1161\/JAHA.119.016173"},{"issue":"11","key":"10330_CR32","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1507\/endocrj.EJ20-0222","volume":"67","author":"M Isshiki","year":"2020","unstructured":"Isshiki M, Sakuma I, Hayashino Y, Sumita T, Hara K, Takahashi K et al (2020) Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration. Endocr J 67(11):1127\u20131138","journal-title":"Endocr J"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-023-10330-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-023-10330-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-023-10330-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T08:15:18Z","timestamp":1697184918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-023-10330-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["10330"],"URL":"https:\/\/doi.org\/10.1007\/s10741-023-10330-5","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,27]]},"assertion":[{"value":"14 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}